Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

Launched by HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY · Aug 19, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness of a new pain relief method for patients undergoing hip replacement surgery. Specifically, it is comparing a combination of liposomal bupivacaine and bupivacaine to a commonly used pain medication called ropivacaine. The researchers want to find out if the new combination provides better pain relief, lasts longer, reduces the need for additional pain medications, and improves patient satisfaction after surgery. They will also be looking at any side effects that participants might experience from using the new medication.

To take part in the study, participants should be between the ages of 65 and 74, have a hip fracture, and be in good overall health (not have serious systemic diseases). Those who are eligible will receive the pain relief treatment before their surgery and will be monitored for pain levels and any complications for up to 72 hours afterward. This trial is not yet recruiting, but it aims to help improve pain management for hip replacement patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • American Society of Anesthesiologists(ASA) I\~II
• • Normal coagulation
• • Clinical diagnosis of hip fracture
• Exclusion Criteria:
• • Presence of severe systemic diseases or ASA grade III or higher
• • Allergy to amide local anesthetics